CAR T cell therapy market is estimated to grow at a CAGR of 12.0% during the forecast period. The major factors contributing to the growth of the market include a significant prevalence of cancer across the globe and rising FDA approvals for cell and gene therapy. As per the World Health Organization (WHO), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. Around 43.8 million people were living with cancer in 2018 and were diagnosed within the last 5 years. This rising prevalence of cancer is attributed to the development of CAR T cell therapy. It is a form of immunotherapy that utilizes specially altered T cells, a part of the immune system to attack cancer. There are currently two CAR T cell therapies approved for the treatment of cancer, which include Yescarta and Kymriah. Yescarta was approved by the US FDA in October 2017, for the treatment of diffuse large B-cell lymphoma (DLBCL). Kymriah was approved by the US FDA in May 2018, for the treatment of adults with certain kinds of non-Hodgkin lymphoma. Kymriah is also approved for the treatment of children and young adults with leukemia. In clinical trials, more than 80% of young adults and children treated with Kymriah achieved cancer remission.

Early results of CAR T-cell therapy to treat lymphoma and other blood cancers are promising. Multiple patients with failed standard treatments or whose blood cancers returned achieved complete success with CAR T cell therapy. As a result, the US FDA is focusing on the approvals of cell and gene therapies. Several CAR T cell therapies are in clinical phases for the treatment of breast cancer, colorectal cancer, and blood cancer. The launch of these novel therapies will likely offer an opportunity for the growth of the market.

Segmental Outlook

The global CAR T cell therapy market is segmented based on application and target antigen. Based on application, the market is classified into non-Hodgkin lymphoma, acute lymphocytic leukemia, and others. Based on target antigen, the market is classified into CD19, CD22, and others.

CD19 target antigen held the largest share in the global CAR T cell therapy market

Among target antigens, CD19 has witnessed considerable growth in 2018. Both CAR-T therapies, including Yescarta and Kymriah available in the market target CD19 for the treatment of several forms of cancers affecting B cells, including leukemia and lymphoma. The advantages related to these CAR-T cell therapies have been shown in clinical trials that have led researchers and biotechnology firms to conduct operations in the CD19 target space. For instance, in November 2019, the University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Co. Ltd. declared an exclusive license agreement and research agreement for the development of blood-derived CAR-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, to treat B-cell malignancies and other cancers. In terms of the agreement, Takeda will get access to the CAR NK platform of MD Anderson and the exclusive rights for the development and commercialization of up to four programs, such as aB-cell maturation antigen (BCMA)-targeted CAR NK-cell therapy and CD19-targeted CAR NK-cell therapy. The emerging clinical trials for CD19 targeted antigen CAR T cell therapy is providing enormous opportunity for the growth of the market.

Regional Outlook

The global CAR T cell therapy market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North America held the largest share in the market owing to the significant prevalence of cancer and significant share in life science research in the region. The presence of major players, including Gilead Sciences, Inc., Pfizer, Inc., and Bristol-Myers Squibb Co. are offering scope for market growth in the region. Increasing US FDA approvals for cell therapy owing to its effectiveness in clinical trials is further providing enormous opportunities for the growth of the market in the region.

Market Players Outlook

The major players in the global CAR T cell therapy market include Novartis International AG, Gilead Sciences, Inc., Pfizer, Inc., Bristol-Myers Squibb Co., and Takeda Pharmaceutical Co. Ltd. These companies are significantly focusing on the development of cell-based therapies as it targets the tumors with more precision, as compared to chemo and radiation therapy. Several partnerships among companies have been reported for the development and commercialization of CAR T cell therapies. For instance, in May 2019, Kite, a Gilead Co., and Humanigen, Inc. declared a clinical partnership for conducting a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta (axicabtageneciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This study aims to define the effect of lenzilumab on Yescarta safety. Kite will be responsible to conduct this study and act as a sponsor for the study.

The Report Covers

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global CAR T cell therapy market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market